Phase 1 Study of SK3530 to Investigate of the Effect of Food

Clinical Trials to Investigate the Influence of Food on Pharmacokinetics of SK3530 in Healthy Male Volunteers.

This study was designed to investigate the food effect of SK3530 on the pharmacokinetics (PKs).

The PDE5 inhibitor, SK3530, is expected to be taken concomitantly with food. The food interaction studies of other PDE5 inhibitors (Viagra, Levitra and cialis) have already accomplished and the results have provided useful information to the patients. The objective of this study is to compare the pharmacokinetics (PKs) of SK3530 and its metabolite (SK3541) under the fasted and fed (low-fat meal and high-fat meal) conditions.

Inclusion Criteria:

• ages 19 to 50
• body weight of (IBM) ± 20%

Exclusion Criteria:

• cardiovascular disease
• color-blindness or weakness